Letko, Brosseau & Associates Inc Biogen Inc. Transaction History

Letko, Brosseau & Associates Inc

$5.12 Billion
Q2 2024

A detailed history of Letko, Brosseau & Associates Inc transactions in Biogen Inc. stock. As of the latest transaction made, Letko, Brosseau & Associates Inc holds 112,672 shares of BIIB stock, worth $19.6 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

112,672

Previous 105,307 6.99%

Holding current value

$19.6 Million

Previous $22.7 Million 15.03%

% of portfolio

0.51%

Previous 0.4%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$190.52 - $236.72 $1.4 Million - $1.74 Million	7,365 Added 6.99%	112,672 $26.1 Million
Q1 2024 May 08, 2024	BUY	$212.02 - $267.71 $189,333 - $239,065	893 Added 0.86%	105,307 $22.7 Million
Q4 2023 Feb 12, 2024	SELL	$222.59 - $267.94 $846,954 - $1.02 Million	-3,805 Reduced 3.52%	104,414 $27 Million
Q3 2023 Nov 09, 2023	SELL	$253.3 - $285.89 $244,687 - $276,169	-966 Reduced 0.88%	108,219 $27.8 Million
Q2 2023 Aug 10, 2023	SELL	$275.25 - $318.06 $1.8 Million - $2.08 Million	-6,540 Reduced 5.65%	109,185 $31.1 Million
Q1 2023 May 11, 2023	SELL	$256.56 - $292.34 $85,434 - $97,349	-333 Reduced 0.29%	115,725 $32.2 Million
Q4 2022 Feb 10, 2023	SELL	$252.44 - $306.72 $825,478 - $1 Million	-3,270 Reduced 2.74%	116,058 $32.1 Million
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $573,362 - $790,614	-2,945 Reduced 2.41%	119,328 $31.9 Million
Q2 2022 Aug 09, 2022	BUY	$187.54 - $223.02 $29,068 - $34,568	155 Added 0.13%	122,273 $24.9 Million
Q1 2022 May 11, 2022	SELL	$193.77 - $244.14 $242,793 - $305,907	-1,253 Reduced 1.02%	122,118 $25.7 Million
Q4 2021 Feb 09, 2022	BUY	$223.92 - $287.77 $755,730 - $971,223	3,375 Added 2.81%	123,371 $29.6 Million
Q3 2021 Nov 03, 2021	SELL	$282.99 - $369.05 $1.31 Million - $1.71 Million	-4,640 Reduced 3.72%	119,996 $34 Million
Q2 2021 Jul 29, 2021	SELL	$259.0 - $414.71 $500,388 - $801,219	-1,932 Reduced 1.53%	124,636 $43.2 Million
Q1 2021 May 11, 2021	SELL	$242.95 - $284.63 $1.05 Million - $1.23 Million	-4,320 Reduced 3.3%	126,568 $35.4 Million
Q4 2020 Feb 05, 2021	SELL	$236.26 - $355.63 $2.53 Million - $3.81 Million	-10,715 Reduced 7.57%	130,888 $32 Million
Q3 2020 Nov 09, 2020	SELL	$264.77 - $305.71 $3.97 Million - $4.58 Million	-14,995 Reduced 9.58%	141,603 $40.2 Million
Q2 2020 Aug 07, 2020	SELL	$258.66 - $342.55 $1.93 Million - $2.55 Million	-7,448 Reduced 4.54%	156,598 $41.9 Million
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $613,784 - $778,594	2,283 Added 1.41%	164,046 $51.9 Million
Q4 2019 Feb 07, 2020	SELL	$220.06 - $304.07 $1.51 Million - $2.09 Million	-6,870 Reduced 4.07%	161,763 $48 Million
Q3 2019 Nov 05, 2019	SELL	$217.44 - $243.88 $2.29 Million - $2.56 Million	-10,515 Reduced 5.87%	168,633 $39.3 Million
Q2 2019 Aug 01, 2019	SELL	$219.29 - $241.72 $1.49 Million - $1.64 Million	-6,795 Reduced 3.65%	179,148 $41.9 Million
Q1 2019 May 10, 2019	SELL	$216.71 - $338.96 $1.16 Million - $1.81 Million	-5,345 Reduced 2.79%	185,943 $44 Million
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $2.92 Million - $3.69 Million	-10,473 Reduced 5.19%	191,288 $57.6 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $1.79 Million - $2.34 Million	-6,087 Reduced 2.93%	201,761 $71.3 Million
Q2 2018 Aug 07, 2018	SELL	$257.52 - $306.91 $74,680 - $89,003	-290 Reduced 0.14%	207,848 $60.3 Million
Q1 2018 May 08, 2018	SELL	$260.13 - $367.91 $1.4 Million - $1.98 Million	-5,375 Reduced 2.52%	208,138 $57 Million
Q4 2017 Feb 20, 2018	SELL	$307.64 - $344.58 $1.32 Million - $1.48 Million	-4,290 Reduced 1.97%	213,513 $68 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $61.2 Million - $71.8 Million	217,803	217,803 $68.2 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Letko, Brosseau & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Letko, Brosseau & Associates Inc with notifications on news.

Account

Letko, Brosseau & Associates Inc Biogen Inc. Transaction History